Guangzhou Kingmed Diagnostics Group Co., Ltd. (603882.SS)
CNY 29.11
(0.55%)
CNY 29.11
(0.55%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 578.98 Million CNY | 1.88% |
| 2022 | 568.29 Million CNY | -8.65% |
| 2021 | 622.09 Million CNY | 34.8% |
| 2020 | 461.5 Million CNY | -24.92% |
| 2019 | 614.66 Million CNY | -17.58% |
| 2018 | 745.8 Million CNY | 29.31% |
| 2017 | 576.77 Million CNY | -18.35% |
| 2016 | 706.42 Million CNY | 73.59% |
| 2015 | 406.95 Million CNY | 1.1% |
| 2014 | 402.53 Million CNY | 71.09% |
| 2013 | 235.27 Million CNY | 56.7% |
| 2012 | 150.14 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 579.41 Million CNY | -17.52% |
| 2024 Q1 | 603.85 Million CNY | 4.3% |
| 2024 Q2 | 702.46 Million CNY | 16.33% |
| 2023 Q4 | 578.98 Million CNY | 1.86% |
| 2023 FY | 578.98 Million CNY | 1.88% |
| 2023 Q1 | 565.85 Million CNY | -0.43% |
| 2023 Q2 | 476.44 Million CNY | -15.8% |
| 2023 Q3 | 568.4 Million CNY | 19.3% |
| 2022 Q3 | 524.04 Million CNY | -5.02% |
| 2022 Q2 | 551.75 Million CNY | -7.43% |
| 2022 Q1 | 596.01 Million CNY | -4.19% |
| 2022 FY | 568.29 Million CNY | -8.65% |
| 2022 Q4 | 568.29 Million CNY | 8.44% |
| 2021 Q1 | 688.93 Million CNY | 49.28% |
| 2021 Q3 | 650.31 Million CNY | -2.2% |
| 2021 Q4 | 622.09 Million CNY | -4.34% |
| 2021 FY | 622.09 Million CNY | 34.8% |
| 2021 Q2 | 664.95 Million CNY | -3.48% |
| 2020 Q4 | 461.5 Million CNY | -23.15% |
| 2020 FY | 461.5 Million CNY | -24.92% |
| 2020 Q1 | 666.75 Million CNY | 8.47% |
| 2020 Q2 | 687.52 Million CNY | 3.11% |
| 2020 Q3 | 600.56 Million CNY | -12.65% |
| 2019 FY | 614.66 Million CNY | -17.58% |
| 2019 Q4 | 614.66 Million CNY | -8.27% |
| 2019 Q3 | 670.09 Million CNY | -8.73% |
| 2019 Q2 | 734.21 Million CNY | -5.73% |
| 2019 Q1 | 778.86 Million CNY | 4.43% |
| 2018 Q1 | 574.54 Million CNY | -0.39% |
| 2018 Q2 | 659.03 Million CNY | 14.71% |
| 2018 FY | 745.8 Million CNY | 29.31% |
| 2018 Q3 | 774.92 Million CNY | 17.58% |
| 2018 Q4 | 745.8 Million CNY | -3.76% |
| 2017 Q3 | 670.78 Million CNY | 4.93% |
| 2017 Q1 | - CNY | -100.0% |
| 2017 FY | 576.77 Million CNY | -18.35% |
| 2017 Q2 | 639.26 Million CNY | 0.0% |
| 2017 Q4 | 576.77 Million CNY | -14.02% |
| 2016 Q4 | 706.42 Million CNY | 0.0% |
| 2016 FY | 706.42 Million CNY | 73.59% |
| 2015 Q3 | 377.73 Million CNY | 0.0% |
| 2015 FY | 406.95 Million CNY | 1.1% |
| 2015 Q4 | 406.95 Million CNY | 7.73% |
| 2014 FY | 402.53 Million CNY | 71.09% |
| 2013 FY | 235.27 Million CNY | 56.7% |
| 2012 FY | 150.14 Million CNY | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Shanghai Runda Medical Technology Co., Ltd. | 6.85 Billion CNY | 91.548% |
| Joinn Laboratories(China)Co.,Ltd. | 85.79 Million CNY | -574.853% |
| WuXi AppTec Co., Ltd. | 5.75 Billion CNY | 89.941% |
| Autobio Diagnostics Co., Ltd. | 1.03 Billion CNY | 44.232% |
| Thalys Medical Technology Group Inc. | 1.05 Billion CNY | 44.919% |
| Chemclin Diagnostics Co., Ltd. | 234.6 Million CNY | -146.787% |